Abstract
Background Third-generation cephalosporin-resistant Gram-negatives (3GCR-GN) and vancomycin-resistant Enterococci (VRE) are common causes of multi-drug resistant healthcare-associated infections, for which gut colonisation is considered a prerequisite. However, there remains a key knowledge gap about colonisation and infection dynamics in high-risk settings such as the intensive care unit (ICU), thus hampering infection prevention efforts.
Methods We performed a three-month prospective genomic survey of infection and gut-colonisation with 3GCR-GN and VRE among patients admitted to an Australian ICU.
Results Among 287 patients screened on admission, 17.4% and 8.4% were colonised by 3GCR-GN and VRE, respectively. Escherichia coli was the most common species (n=36 episodes, 58.1%) and the most common cause of 3GCR-GN infection. Only two VRE infections were identified. The rate of infection among patients colonised with E. coli was low, but higher than those who were not colonised on admission (6% vs 2% E. coli, p=0.3). While few patients were colonised with 3GCR-Klebsiella pneumoniae or Pseudomonas aeruginosa on admission (n=4), all such patients developed infections with the colonising strain. Genomic analyses revealed 10 putative nosocomial transmission clusters: four VRE, six 3GCR-GN, with epidemiologically linked clusters accounting for 21% and 6% of episodes, respectively (OR 4.3, p=0.02).
Conclusions 3GCR-E. coli and VRE were the most common gut colonisers. E. coli was the most common cause of 3GCR-GN infection, but other 3GCR-GN species showed greater risk for infection in colonised patients. Larger studies are warranted to elucidate the relative risks of different colonisers and guide the use of screening in ICU infection control.
Key points Surveillance for VRE or ESBL Gram-negative bacteria in ICU showed distinct species-specific clinical risk profiles. VRE and ESBL-Escherichia coli were the most common colonisers, but were associated with lower attack rate and transmission rate, compared with rarer coloniser Klebsiella pneumoniae.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Health and Medical Research Council of Australia (Project Grant 1043822, Investigator Grant APP1176192 to Kelly L Wyres), the Viertel Charitable Foundation of Australia (Senior Medical Research Fellowship to Kathryn E Holt) and the Bill and Melinda Gates Foundation of Seattle (grant OPP1175797 to Kathryn E Holt).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Alfred Health Human Research Ethics Committee, Project numbers #550/12 (19 February 2013) and #526/13 (10 December 2013).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data supporting the manuscript are provided within the main document and/or supplementary materials, or via public data repositories (European Nucleotide Archive, Genbank and/or Figshare) as specified within the manuscript materials.
